A pharma giant is moving past one patent cliff — but another is already looming
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Mercati
A pharma giant is moving past one patent cliff — but another is already looming
TradeNews BD, nota equity-FX-crypto (2026-10-30): Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks. Fonte primaria: originale su CNBC Top News (cnbc.com).